Cumulus Neuroscience, a leading innovator in brain health technology for clinical trials, today announced the publication of ...

The hair follicle is a highly dynamic mini-organ that undergoes cyclic phases of growth, regression, and rest. The anagen ...

A device smaller than a grain of dust is emerging as a surprisingly powerful candidate to reshape how quantum computers are ...

Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced that the first participant has been dosed in the ...

Lysoway Therapeutics, Inc., a biotechnology company advancing structure-guided small-molecule modulators of lysosomal ion channels to treat age-related neurodegeneration, today announced that its lead ...

Newron Pharmaceuticals further expands its intellectual property portfolio for Evenamide with a new EU composition of matter ...

The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) ...

Impressively, the unit registered the lowest frequency loss of any chip to date. Specifically, the engineers noted that the new chip was 15x more stable and 100x more efficient in terms of microwave ...

Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...

Kyocera Corporation (President: Hideo Tanimoto; “Kyocera”)(TOKYO: 6971) announced that it has developed a new meta-lens that ...

M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.

Curious to find out all the requirements for the different phases of the 2nd Expedition Project? Here is what players need to ...